Meyka Pro banner
SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. (SLS) Stock Overview

Explore SELLAS Life Sciences Group, Inc.’s financial performance, market position, analyst ratings, and future outlook.

SLS●NASDAQ
HealthcareBiotechnology
$17.95
$1.20(6.27%)
U.S. Market opens in 2h 36m

SELLAS Life Sciences Group, Inc. (SLS)

Meyka AI Score

Z

Key Financials

Market Cap3.7B
P/E Ratio-95.65
EPS (TTM)$-0.21
ROE-0.32%
Fundamental Analysis

AI Price Forecasts

1 Month$8.38
3 Months$14.00
1 Year Target$13.64

SLS Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, SELLAS Life Sciences Group, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of SLS on the NASDAQ shows an RSI of 73.38, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $13.64 for the NASDAQ listing.

Key metrics behind SELLAS Life Sciences Group, Inc.'s NASDAQ-traded stock include a P/E ratio of -95.65 and a market capitalization of 3.7B. Combined with our AI analysis, these give both institutional and retail investors a clear view of SLS on the NASDAQ.

Price Performance (NASDAQ: SLS)

1-Day Change
-6.27%
5-Day Change
106.56%
1-Month Change
79.86%
3-Month Change
37.02%
6-Month Change
146.23%
Year-to-Date (YTD) Change
376.13%
1-Year Change
1028.93%
3-Year Change
1728.65%
5-Year Change
161.28%
All-Time (Max) Change
-99.99%

Contact Information

646 200 5278
7 Times Square, New York, NY, 10036

Company Facts

130 Employees
IPO DateMar 12, 2008
CountryUS
Actively Trading

Frequently Asked Questions